Log in

NYSE:BHCBausch Health Companies Stock Price, Forecast & News

$19.13
+0.86 (+4.71 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.29
Now: $19.13
$19.49
50-Day Range
$17.02
MA: $18.25
$20.07
52-Week Range
$11.15
Now: $19.13
$31.97
Volume2.82 million shs
Average Volume3.46 million shs
Market Capitalization$6.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Read More
Bausch Health Companies logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.60 billion
Cash Flow$10.99 per share
Book Value$3.22 per share

Profitability

Net Income$-1,788,000,000.00

Miscellaneous

Employees21,700
Market Cap$6.79 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$19.13
+0.86 (+4.71 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

How has Bausch Health Companies' stock been impacted by COVID-19 (Coronavirus)?

Bausch Health Companies' stock was trading at $18.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BHC stock has increased by 3.7% and is now trading at $19.13.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Bausch Health Companies?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bausch Health Companies
.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Bausch Health Companies
.

How can I listen to Bausch Health Companies' earnings call?

Bausch Health Companies will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.88 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.88. The firm earned $2.01 billion during the quarter, compared to analyst estimates of $2.03 billion. Bausch Health Companies had a negative net margin of 21.96% and a positive return on equity of 84.58%. The firm's revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.03 earnings per share.
View Bausch Health Companies' earnings history
.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2020 Pre-Market earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.8-8.2 billion, compared to the consensus revenue estimate of $8.44 billion.

What price target have analysts set for BHC?

16 analysts have issued 1-year price targets for Bausch Health Companies' shares. Their forecasts range from $14.00 to $64.00. On average, they anticipate Bausch Health Companies' share price to reach $30.88 in the next year. This suggests a possible upside of 61.4% from the stock's current price.
View analysts' price targets for Bausch Health Companies
.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch’s Bausch + Lomb/International and Salix segments maintain momentum on the back of several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, continue to perform well too. The initial uptake of psoriasis lotion, Duobrii, has been encouraging as well. After a tumultuous period, the company started a rebuilding process. Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company’s performance is expected to be strong. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far." (12/16/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)

Has Bausch Health Companies been receiving favorable news coverage?

News headlines about BHC stock have trended somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Bausch Health Companies earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Bausch Health Companies
.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in July. As of July 15th, there was short interest totaling 19,050,000 shares, an increase of 9.7% from the June 30th total of 17,370,000 shares. Based on an average daily volume of 5,130,000 shares, the short-interest ratio is currently 3.7 days. Currently, 5.5% of the company's shares are short sold.
View Bausch Health Companies' Current Options Chain
.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Constellation Software (CSU), Intact Financial (IFC), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Bank of America (BAC), Twitter (TWTR) and Advanced Micro Devices (AMD).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the following people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ardevora Asset Management LLP (0.70%), Assenagon Asset Management S.A. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.32%), CIBC Asset Management Inc (0.19%), Intact Investment Management Inc. (0.14%) and UBS Group AG (0.07%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries.
View institutional ownership trends for Bausch Health Companies
.

Which institutional investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, M&G Investment Management Ltd., Zurcher Kantonalbank Zurich Cantonalbank , Sumitomo Mitsui Trust Holdings Inc., SG Americas Securities LLC, B & T Capital Management DBA Alpha Capital Management, Cutler Group LP, and Sanders Morris Harris LLC. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann, and Mark C Mckenna.
View insider buying and selling activity for Bausch Health Companies
.

Which institutional investors are buying Bausch Health Companies stock?

BHC stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Ardevora Asset Management LLP, Intact Investment Management Inc., CIBC Asset Management Inc, Thompson Investment Management Inc., Raymond James & Associates, Paragon Capital Management LLC, and Nisa Investment Advisors LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio, and William D Humphries.
View insider buying and selling activity for Bausch Health Companies
.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $19.13.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $6.79 billion and generates $8.60 billion in revenue each year. The company earns $-1,788,000,000.00 in net income (profit) each year or $4.43 on an earnings per share basis. Bausch Health Companies employs 21,700 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is www.bauschhealth.com.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.